No — BPC-157 is not FDA-approved for any use, and the July 23, 2026 advisory committee vote did not change that. That day, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) considered whether BPC-157 should be added to the list of bulk drug substances that state-licensed 503A pharmacies may use to compound medications, and the committee…
No — BPC-157 is not FDA-approved for any use, and the July 23, 2026 advisory committee vote did not change that. That day, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) considered whether BPC-157 should be added to the list of bulk drug substances that state-licensed 503A pharmacies may use to compound medications, and the committee reportedly voted 8–6, with one abstention, in favor. That vote is a recommendation, not a decision. FDA’s own reviewers had advised against adding BPC-157, and as of October 2026 the agency has not proposed or finalized any rule that would put it on the list. This explainer walks through what the BPC-157 FDA review actually decided, what it did not, and what is known — and unknown — about safety.
FDA status (facts as of October 23, 2026): BPC-157 is not FDA-approved for any indication, is not on the 503A Bulks List, and no proposed or final rule adding it has been published in the Federal Register. This article is educational, is not a recommendation to use BPC-157, and is not medical advice (see our medical disclaimers). Consult a licensed clinician before making any decision about an unapproved substance.
| Question | Answer |
|---|---|
| Is BPC-157 FDA-approved? | No — not for any use |
| Is it on the 503A Bulks List? | No |
| Is it still in FDA’s “Category 2” (significant safety risks)? | No — FDA now lists it as “nominated but withdrawn” |
| What did the committee vote on? | Whether to place it on the 503A Bulks List, evaluated for ulcerative colitis; the free base and acetate forms were separate questions |
| Committee outcome | 8 yes, 6 no, 1 abstention, as reported by news outlets; official minutes not yet posted |
| FDA staff position | Recommended against inclusion |
| Is the vote binding? | No |
| Next legally required step | A proposed rule with public comment, then a final rule |
| Banned in competitive sport? | Yes — WADA category S0, non-approved substances |
The Pharmacy Compounding Advisory Committee is an outside expert panel. The Federal Register notice published April 16, 2026 describes its function as providing “advice and recommendations to FDA,” and the FDA meeting page itself states that “advisory committees make non-binding recommendations to the FDA.” The July 23–24, 2026 meeting reviewed seven peptides; BPC-157 was discussed on July 23.
The official voting questions did not ask whether BPC-157 works or whether it should be approved. They asked two separate list-placement questions: “Should BPC-157 (free base) be placed on the list?” and “Should BPC-157 acetate be placed on the list?” The free base and the acetate salt are treated as different bulk drug substances.
The only use FDA evaluated was ulcerative colitis (UC, a chronic inflammatory bowel disease of the colon). According to the FDA briefing document on BPC-157, the substance was also nominated for Crohn’s disease, celiac disease and tendonitis, but FDA did not evaluate those uses because the nominations “did not include sufficient information” to do so, and the agency found no clinical studies in those populations.
FDA had not posted official minutes, a transcript or vote results on the meeting page as of October 23, 2026. The 8–6 vote with one abstention was reported by ABC News, which noted the vote is “non-binding and still needs sign-off from the FDA,” and was confirmed by TIME. News reports give a single tally, so it is not publicly documented whether that tally applied to one form or both.
BPC-157 was one of seven substances reviewed. Coverage of FDA peptides at this meeting is easy to blur together, so here is each substance with the use FDA evaluated, from the FDA meeting page, and the outcome as reported by AJMC and TIME. Outlets disagree on exact margins for some substances, so only the direction of each vote is shown.
| Substance | Use FDA evaluated | Committee outcome (as reported) |
|---|---|---|
| BPC-157 | Ulcerative colitis | Recommended |
| KPV | Wound healing and inflammatory conditions | Recommended |
| TB-500 | Wound healing | Recommended |
| MOTS-c | Obesity and osteoporosis | Recommended |
| Semax | Cerebral ischemia, migraine, trigeminal neuralgia | Recommended |
| Epitalon | Insomnia | Recommended |
| Emideltide (DSIP) | Opioid withdrawal, chronic insomnia, narcolepsy | Not recommended |
As AJMC summarized: “None of the peptides have been added to the 503A Bulks List, and none is an FDA-approved drug.”
Social media posts declaring “FDA approved BPC-157!” misread the process. So, is BPC-157 FDA approved after the vote? No, for four reasons:
Compounding means a pharmacist combines or alters ingredients to make a medication for an individual patient. Under section 503A of the federal Food, Drug, and Cosmetic Act, FDA’s 503A bulk drug substances page explains that a 503A pharmacy may compound with a bulk drug substance only if it (1) has a USP or National Formulary monograph, (2) is a component of an FDA-approved drug, or (3) appears on the 503A Bulks List. Larger 503B “outsourcing facilities” are a separate category that must follow federal manufacturing-quality standards (CGMP), while state boards of pharmacy handle most day-to-day oversight of 503A pharmacies.
The 503A Bulks List grows slowly. The February 2019 final rule placed six substances on it, and a September 2019 proposed rule (five substances to add, 26 not to add) was still awaiting finalization as of FDA’s May 2026 page update.
Because the same few labels get confused online, here is what each one actually means:
| Label | What it means | Did FDA review safety and effectiveness of the product? |
|---|---|---|
| FDA-approved | A specific product approved for specific indications after clinical trials — for example, Tirzepatide (Mounjaro®, Zepbound®) | Yes, for the approved uses |
| On the 503A Bulks List | An ingredient a 503A pharmacy may compound with, on a prescription for an individual patient | No — the finished compounded drug is not FDA-approved |
| Compounded | Made by a pharmacy for an individual patient | No |
| Category 2 (interim policy) | Nominated substances FDA identified as potentially raising significant safety risks | No — a risk flag, not a review of a product |
| “Nominated but withdrawn” | The nominator withdrew its request; BPC-157’s current listing | No — and FDA says withdrawal is not a determination about the substance |
| “Research use only” | A seller’s label stating the product is not for human use | No |
As of October 2026, BPC-157 meets none of the three 503A conditions: the FDA briefing confirms there is no USP or National Formulary monograph, there is no approved product containing it in any country, and it is not on the bulks list. A Federal Register search on October 23, 2026 returned only one document mentioning BPC-157 — the April 2026 meeting notice — and no proposed or final rule. State pharmacy laws add their own requirements, and this article is not legal advice.
Most coverage of FDA’s 2023 peptide restrictions and the 2026 reversal relies on news dates that conflict. Every row below is drawn from FDA or Federal Register records, except where a news source is named.
| Date | What happened | Source |
|---|---|---|
| 1993 | Earliest published research FDA cites; FDA says BPC-157 was first synthesized in Croatia in the early 1990s | FDA BPC-157 briefing document |
| September 29, 2023 | Added to FDA’s Category 2 list (substances that may present significant safety risks) for 503A compounding | FDA Category 2 listing (archived version of FDA’s safety-risk page) |
| Date not stated by FDA | Both nominations (from Wells Pharmacy Network and from LDT Health Solutions/International Peptide Society) withdrawn; FDA chose to evaluate both forms “on its own initiative” | FDA BPC-157 briefing document |
| April 16, 2026 | Federal Register notice announces the July meeting and opens public docket FDA-2025-N-6895 | Federal Register |
| By April 22, 2026 | FDA’s safety-risk page lists BPC-157 among substances “nominated but withdrawn,” no longer in Category 2 | FDA |
| July 23, 2026 | Advisory committee votes on list placement; 8–6 with one abstention in favor, as reported | FDA meeting page; ABC News, TIME |
| As of October 23, 2026 | No official minutes posted; no proposed or final rule in the Federal Register | FDA; Federal Register |
Regulatory timelines for investigational drugs rarely move in a straight line — our explainer on retatrutide’s side effects and FDA timeline covers a very different path: a drug going through formal clinical trials.
BPC-157 left Category 2 because its nominators withdrew their nominations — not because FDA found it safe. FDA’s interim policy guidance on 503A bulk substances says withdrawal of a nomination “and if applicable, a resulting update to the categories described in this guidance, do not reflect a determination by FDA regarding the validity of the nomination,” and that “FDA may continue to evaluate a substance at its discretion even if the nominator submits a comment requesting withdrawal of the nomination.” That is exactly what happened here.
FDA’s current page on bulk substances that may present significant safety risks still describes BPC-157’s risks: possible immunogenicity for certain routes of administration, concerns about peptide-related impurities and characterization of the active ingredient, and “no, or only limited, safety-related information for the proposed routes of administration.”
FDA weighs four criteria for every nominated substance, under a balancing test set by its February 2019 final rule. The BPC-157 briefing concluded against inclusion on each:
| 503A criterion | What FDA’s reviewers concluded |
|---|---|
| Physical and chemical characterization | “Not well-characterized,” citing inconsistent naming and missing data on identity, purity, peptide-related impurities, aggregates and microbial quality (including bacterial endotoxins) |
| Safety | Animal signals affecting clotting and the liver; possible significant immunogenicity risk for injected and nasal routes; “insufficient information to support patient safety for the long-term use” |
| Effectiveness | “A lack of evidence to make a conclusion on the effectiveness of BPC-157 for treating UC” |
| Historical use in compounding | Available data “too limited for FDA to understand the historical use” of BPC-157 in compounded drugs |
| Overall | “A balancing of the criteria weighs against” placing either form on the list |
For anyone living with UC, the more practical point is that FDA-approved treatments already exist. The briefing lists multiple approved options, including 5-aminosalicylates (such as mesalamine), corticosteroids, biologics and oral S1P receptor modulators. The current American College of Gastroenterology UC guideline (Rubin et al., 2025) does not include BPC-157, according to FDA’s review. UC management belongs with a gastroenterologist who can match treatment to disease severity.
Whether BPC-157 is safe for people is mostly an open question, because so little human research exists. FDA’s briefing identified five published clinical studies, plus one registered trial that never posted results:
| Study population | Route | Participants | Duration | Main limitation |
|---|---|---|---|---|
| Healthy volunteers | Rectal enema | 24 | 8 days | Meeting abstract only; limited safety detail |
| Mild-to-moderate UC | Rectal enema | 53 randomized, 46 completed | 2 weeks | Meeting abstract; difference vs. placebo not established |
| Knee pain | Injection into the knee joint | 17 | One or two injections, retrospective follow-up | No control group; phone-survey outcomes |
| Interstitial cystitis | Injection into the bladder wall | 12 | Single procedure | No control group |
| Healthy volunteers | IV infusion | 2 | 2 days | Pilot study |
| Healthy volunteers (registered Phase 1 trial) | Oral | 42 planned (estimated enrollment) | — | Status “unknown”; no results posted |
The only UC trial, the 2005 meeting abstract, randomized 53 people to a BPC-157 enema or placebo for two weeks. FDA found the estimated difference from placebo uncertain enough that no conclusion about effectiveness could be drawn. None of the studies used the oral, under-the-skin, nasal or skin-cream forms that were proposed for compounding.
The small studies are worth reading as examples of the evidence base: a 2025 pilot study of IV BPC-157 (Lee and Burgess) enrolled two participants, and a 2021 knee-pain report (Lee and Padgett) was a retrospective review based on phone follow-up, without validated outcome measures. The registered oral trial, NCT02637284, was last updated in 2015 and has no posted results.
A 2025 systematic review in the HSS Journal (Vasireddi et al.) screened 544 records and included 36 studies on BPC-157 in sports medicine — 35 preclinical and only one clinical. The authors concluded that its safety in humans is unknown and that clinicians and athletes “should exercise caution.”
BPC-157 safety data is thin in both directions: there is no large trial showing harm, and no large trial showing it is safe. Here is what FDA’s review found about BPC-157 side effects and risks:
The U.S. Anti-Doping Agency sums up the state of the evidence plainly: “it is unknown if there is a safe dose.” Compare that with an approved medication, which has a labeled side-effect profile drawn from large trials — see, for example, our overview of Semaglutide side effects.
Products sold online labeled “research use only” or “not for human consumption” sit outside FDA’s compounding framework entirely. No regulator verifies what is in them. FDA’s review itself flagged inconsistent naming and missing identity and purity data for BPC-157, and one of the three FAERS reports involved a product labeled “research purposes only.” A label like that tells you nothing about what the product contains, whether it is sterile, or how much active ingredient it holds.
If you have used a BPC-157 product and notice any of the following, get medical care. These are general warning signs, not a diagnosis:
Bring the product or its label so the clinician knows exactly what was used. Side effects can be reported to the FDA through MedWatch, which matters because FDA’s briefing notes that 503A compounders generally do not report adverse events to the agency. For non-urgent questions, you can contact our clinic.
FDA can accept or reject the committee’s advice. If it moves forward with any of the FDA peptides from this meeting, the legally required path runs through a proposed rule in the Federal Register, a public comment period, and a final rule. There is no statutory deadline: the September 2019 proposed rule on other bulk substances had still not been finalized as of FDA’s May 2026 update.
Even if BPC-157 were eventually listed, it would still not be an FDA-approved drug. A 503A pharmacy could compound it only on a prescription for an individual patient, under state pharmacy rules, without FDA review of the finished product. TIME also reported that an FDA quality official told the panel the agency lacks authority to impose some of the quality “guardrails” committee members asked for. Approved peptide medications took the opposite route, through full clinical trial programs — our Ozempic®, Wegovy® and Mounjaro GLP-1 comparison shows what that evidence looks like.
To follow developments, watch the FDA meeting page (for minutes), the Federal Register (for any proposed rule), and public docket FDA-2025-N-6895.
When patients ask about any unapproved substance, our clinicians start with an evaluation, not the product — medical history, labs and the actual diagnosis first, then FDA-approved options for that diagnosis. That is the core of our approach. Questions worth asking any licensed clinician:
Our team can review the evidence with you and explain where an unapproved substance stands. If you are new to the clinic, getting started explains what the first visit involves, and you can meet our clinical team before you book.
Peptide headlines change monthly; good medicine shouldn’t. Cardiomender Weight Loss & Aesthetics has provided in-person, physician-supervised care in Pembroke Pines since 2009 — more than 15 years of weight-loss medicine that predates the GLP-1 era. What that means for patients asking about trending substances:
No. The July 23, 2026 vote was an advisory recommendation about whether BPC-157 could be used as a compounding ingredient, not a drug approval. BPC-157 is not FDA-approved for any use, and FDA had not acted on the recommendation as of October 2026.
It depends on what “legal” means. BPC-157 is not an approved drug, and under 503A a pharmacy may compound only with substances that have a USP monograph, are part of an approved drug, or are on the bulks list — BPC-157 meets none of these as of October 2026. State pharmacy boards also regulate compounding. This is general information, not legal advice.
Because the organizations that nominated it withdrew their nominations. FDA’s interim policy says a withdrawal does not reflect an FDA determination about the substance, and FDA went on to evaluate BPC-157 on its own initiative — recommending against it.
That isn’t known yet. FDA has said it will not make a final determination until it has considered the committee’s input and finalized its reviews. Any listing would require a proposed rule, public comment and a final rule, and that process has no fixed deadline.
FDA concluded there is not enough information to establish its safety, especially for long-term use, and flagged possible immunogenicity and impurity risks. Whether peptides are safe in general depends on the specific substance, product and evidence — there is no single answer for the whole category.
No human study has shown liver damage. However, 28-day animal studies reviewed by FDA found liver-associated lab changes, including raised ALT, and no long-term human data exist to rule out a risk. Anyone with liver disease should discuss any supplement or unapproved substance with a clinician.
Some specific peptide medications are, for specific uses — “peptide” is not an approval category. For example, the FDA approved Zepbound on November 8, 2023 for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition, alongside diet and exercise. Our guide to peptides for weight loss explains what peptides are FDA approved for weight management, and our Semaglutide vs. Tirzepatide comparison covers the two most widely used.
It lists bulk ingredients that licensed 503A pharmacies may use to compound medications for individual patients when the ingredient has no USP monograph and is not part of an approved drug. Being listed does not make a compounded product FDA-approved.
Ulcerative colitis only. It had also been nominated for Crohn’s disease, celiac disease and tendonitis, but FDA did not evaluate those uses because the nominations lacked sufficient information and no clinical studies were found.
Yes. BPC-157 is on the World Anti-Doping Agency’s prohibited list under S0, non-approved substances, and USADA notes it is “not approved for human clinical use” by the FDA or any other global health authority. Competitive athletes can test positive for it.
Seek care based on the warning signs above — call 911 for breathing trouble or facial swelling — and bring the product label with you. Report the reaction to FDA MedWatch, and consult a licensed clinician before using any unapproved substance again. More answers about medically supervised care are in our weight loss FAQ.
Have questions about a peptide you’ve read about, or about FDA-approved options for your health goals? Schedule a consultation at Cardiomender Weight Loss & Aesthetics in Pembroke Pines, serving patients across South Florida. Call (954) 799-6439 or request an appointment online.
Our physician-supervised weight loss and aesthetic programs are designed around your unique body, goals, and lifestyle.
